Skip to main content
Home

Main navigation

  • About HIPRA

      About HIPRA

    • Discover HIPRA
    • History
    • Sustainability & CSR
    • HIPRA Around the World
  • Animal Health
  • Human Health

      Human Health

    • Products & Services
      • Covid-19 Vaccine
      • Analysis Covid-19
      • GoodGut: digestive health
    • R&D projects
    • News
    • Press
  • Careers
  • Contact us
Career
Search
Search
who we are

News

HIPRA joins the "Voluntary Agreements Program"

Corporate
Explore
voluntary commitment

EMA starts rolling review of Covid-19 HIPRA’s vaccine

Human
Explore
European Medicines Agency

GoodGut and Vall d'Hebron are studying the implementation of the first non-invasive diagnostic test to detect Irritable Bowel Syndrome

Human
Explore
goodgut news

AEMPS authorizes phase III clinical trial of the HIPRA’s vaccine against Covid-19

Human
Explore
Phase III

The European RBDCOV project will study HIPRA’s Covid-19 vaccine in children, adolescents and immunocompromised patients

Human
Explore
RBDCOV

HIPRA plans to produce 400 million doses of its SARS-CoV-2 HIPRA vaccine during 2022

Human
Explore
Sanchez Visit
  • Load More
Home

Footer second

  • About HIPRA
  • Animal Health
  • Human Health

Footer third

  • Careers
  • Contact us

Footer fourth

  • LinkedIn
  • YouTube

© HIPRA 2022

Footer

  • Terms of use
  • Privacy policy
  • Cookies policy